Tallon Kerry Patrick Buys Shares of 19,114 Pfizer Inc. (NYSE:PFE)

Tallon Kerry Patrick bought a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel reports. The institutional investor bought 19,114 shares of the biopharmaceutical company’s stock, valued at approximately $509,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Bradley Foster & Sargent Inc. CT grew its stake in Pfizer by 3.2% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company’s stock valued at $7,586,000 after purchasing an additional 8,375 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Pfizer by 0.6% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company’s stock worth $25,099,000 after acquiring an additional 5,246 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of Pfizer by 1.4% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company’s stock worth $5,339,000 after acquiring an additional 2,572 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Pfizer by 85.9% during the 2nd quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company’s stock worth $54,654,000 after acquiring an additional 902,376 shares in the last quarter. Finally, Sienna Gestion boosted its stake in shares of Pfizer by 0.8% during the 2nd quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company’s stock worth $6,189,000 after acquiring an additional 1,771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.1 %

Pfizer stock opened at $26.51 on Friday. The business has a 50 day moving average price of $26.11 and a two-hundred day moving average price of $28.01. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.49%. Pfizer’s dividend payout ratio is 227.03%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PFE. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Finally, Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.